Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity

NAD depletion by FK866 induces autophagy

(2014) Richard A. Billington et al.   Autophagy

Intracellular NAD+depletion induces autophagic death in multiple myeloma cells

(2012) Michele Cea et al.   Autophagy

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition

(2012) M. Cea et al.   BLOOD

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Reciprocal Potentiation of the Antitumoral Activities of FK866, an Inhibitor of Nicotinamide Phosphoribosyltransferase, and Etoposide or Cisplatin in Neuroblastoma Cells

(2011) C. Travelli et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Compromising the Unfolded Protein Response Induces Autophagy-Mediated Cell Death in Multiple Myeloma Cells

(2011) Anne-Sophie Michallet et al.   PLoS One

Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes

(2010) E. David et al.   BLOOD

The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling Pathways

(2010) Riekelt H. Houtkooper et al.   ENDOCRINE REVIEWS

Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells

(2010) Gabriele Zoppoli et al.   EXPERIMENTAL HEMATOLOGY

Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (

(2010) Christopher P. Venner et al.   LEUKEMIA & LYMPHOMA

The NF- B Inhibitor LC-1 Has Single Agent Activity in Multiple Myeloma Cells and Synergizes with Bortezomib

(2010) E. J. Walsby et al.   MOLECULAR CANCER THERAPEUTICS

APO866 activity in hematologic malignancies: a preclinical in vitro study

(2009) M. Cea et al.   BLOOD

The NAD biosynthesis inhibitor APO866 has potent antitumor activity against hematologic malignancies

(2009) A. Nahimana et al.   BLOOD

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors

(2009) M. Watson et al.   MOLECULAR AND CELLULAR BIOLOGY

Catastrophic NAD+ Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE

(2009) Santina Bruzzone et al.   PLoS One

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells

(2008) S. Markovina et al.   MOLECULAR CANCER RESEARCH